By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Emergent BioSolutions 

2273 Research Boulevard
Suite 400
Rockville  Maryland  20850  U.S.A.
Phone: 301-795-1800 Fax: 301-795-1899

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.

Key Statistics

Ownership: Public

Web Site: Emergent BioSolutions
Symbol: EBS

Company News
Integrated BioTherapeutics Announces Licensing Agreement With Emergent BioSolutions (EBS) For Development Of Equine Immunoglobulin Therapeutics For Filovirus Infections 11/15/2016 8:11:49 AM
Anthrax Vaccine Maker Emergent BioSolutions (EBS) Lays Off 91 in Michigan 10/6/2016 5:46:40 AM
Emergent BioSolutions (EBS) Provides Update On Status Of Biothrax Procurement Contract And Discussions With CDC 10/3/2016 7:46:48 AM
Emergent BioSolutions (EBS) Spinoff Aptevo Therapeutics (APVO) Closes $35 Million Loan Agreement 8/5/2016 7:36:11 AM
3 Biotech Stocks to Withstand the Presidential Race 4/20/2016 8:02:35 AM
Ligand (LGND) Enters Into OmniAb Platform License Agreement With Emergent BioSolutions (EBS) 1/13/2016 10:00:34 AM
Emergent BioSolutions (EBS) Announces Preliminary 2015 Financial Results, Provides 2016 Financial Outlook, And Outlines New Five-Year (2016-2020) Strategic Growth Plan 1/11/2016 8:34:06 AM
Biowarfare Company Emergent BioSolutions (EBS)' Cancer Spinoff Aptevo Therapeutics to Employ 70 - 90 in Seattle 12/29/2015 7:46:57 AM
FDA Approves Emergent BioSolutions (EBS)' BioThrax For Post-Exposure Prophylaxis 11/25/2015 9:10:36 AM
Emergent BioSolutions (EBS) To Release Third Quarter 2015 Financial Results And Conduct A Conference Call On November 5, 2015 10/22/2015 8:32:24 AM